Table 1.
Patient characteristics.
| Parameter | Value* |
|---|---|
| No. of participants (women/men) | 24(7/17) |
| Age (years) | 63 ± 12 |
| TNM: | |
| T2/T3/T4 | 1/17/6 (4 %/70 %/25 %) |
| N0/N1/N2 | 7/11/6 (29 %/46 %/25 %) |
| M0/M1 | 21/3 (88 %/13 %) |
| Stage (AJCC): | |
| 1 | 2 (8 %) |
| 2 | 4 (17 %) |
| 3 | 15 (63 %) |
| 4 (resectable liver metastasis) | 3 (13 %) |
| Treatment: | |
| Short-course radiotherapy (5 × 5 Gy) | 6 (25 %) |
| Long-course radiotherapy (2 × 25 Gy) with concomitant chemotherapy | 18 (75 %) |
| Timing: | |
| Weeks from first MR to radiotherapy | 4.5 (1) |
| Weeks from end of radiotherapy to follow-up MRI | 5 (1) |
| Weeks from end of radiotherapy to surgery | 8.5 (1.5) |
| ypT: | |
| 0/1/2/3/4 | 5/2/3/12/2 (21 %/8%/13 %/50 %/8%) |
| ypN: 0/1/2 | 15/5/4 (63 %/21 %/17 %) |
| Tumour volume: | |
| Volumepre (cm3) | 30 ± 25 |
| Volumepost (cm3) | 15 ± 9 |
| ΔVolume (%) | − 52 ± 22 |
| Blood flow (BF): | |
| BFpre (ml/min/100 g) | 104 ± 26 |
| BFpost (ml/min/100 g) | 89 ± 37 |
| ΔBF (%) | −11 ± 37 |
| Diseased: | |
| Women | 1 (14 %)** |
| Men | 6 (35 %) |
*Quantity (percentage) or mean (SD) as appropriate.
**Percentage of women/men in study.